Information regarding the activation profile and responsiveness of JCV-specific CD8+ T-cells from DMF-treated patients will be needed to determine how this population varies over the course of treatment and whether it can be used to assay risk for PML. The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.